Brief: Cue Biopharma Receives FDA Acceptance Of IND Application For CUE-102 In WT1

Cue Biopharma

11/05/2022 13:25

May 11 (Reuters) - Cue Biopharma Inc  CUE.O :
    * CUE BIOPHARMA RECEIVES FDA ACCEPTANCE OF INVESTIGATIONAL
NEW
DRUG (IND) APPLICATION FOR CUE-102 IN WILMS’ TUMOR 1 (WT1) -
EXPRESSING CANCERS
    * CUE BIOPHARMA INC - TO INITIATE PHASE 1 DOSE ESCALATION
AND
EXPANSION TRIAL FOR TREATMENT OF WILMS' TUMOR 1 (WT1) POSITIVE
RECURRENT/METASTATIC CANCERS
    * CUE BIOPHARMA - STARTING DOSE OF 1 MG/KG EXPECTED TO
REDUCE TIME
AND COST OF DOSE ESCALATION PHASE OF TRIAL, SUPPORTING
DEVELOPMENT EFFICIENCY OF CUE-100 SERIES PLATFORM

Source text for Eikon:  ID:nGNX74MDBX 
Further company coverage:  CUE.O 

 ((Reuters.Briefs@thomsonreuters.com;))